<DOC>
	<DOC>NCT01039428</DOC>
	<brief_summary>This was a study to evaluate the efficacy and safety of HS219, chitosan-loaded chewing gum, when given three times a day for 3 weeks to the hemodialysis (HD) patients with hyperphosphatemia whose serum inorganic phosphorus was not well controlled with calcium carbonate or sevelamer hydrogen chloride.</brief_summary>
	<brief_title>A Study of HS219 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<criteria>Written informed consent given Able to comply with the study procedures and medication On a stable HD regimen (at least 3 x per week) for ≥ 3 months Subject receiving calcium carbonate or sevelamer hydrochloride as a phosphate binder at screening, must have been on a stable regimen (dose and medication) for at least 1 month A mean serum inorganic phosphorous in the previous 3 tests : &gt; 5.5 mg/dL and &lt; 9.0 mg/dL Removal rate of blood urea nitrogen (BUN) ≥ 60% Rate of salivary flow by Saxon test ≥ 1 g/2 min Blood purification therapy other than HD Current clinically significant intestinal motility disorder Possible parathyroid intervention during the study period History of malignancy and severe cardiovascular disorders such as heart disease, angina, congested heart failure, valve stenosis, atrial fibrillation and arrhythmia History of allergy against active ingredient Receipt of any investigational drug within 30 days of informed consent</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>hyperphosphatemia</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>chitosan</keyword>
</DOC>